Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

ProfoundBio Makes $246 Million Deal for Synaffix Linker-Payload Technology

publication date: Jul 22, 2021

ProfoundBio, a Seattle-Suzhou antibody-drug conjugate company, acquired non-exclusive rights to use novel linker-payload technologies from Amsterdam's Synaffix. It will make up to $246 million in upfront and milestone payments, plus tiered royalties on sales. ProfoundBio will have rights to use Synaffix's two linker technologies, GlycoConnect™ glycan conjugation and HydraSpace™ polar spacer, for a specific tumor associated antigen along with an option for a second TAA. Two weeks ago, ProfoundBio closed a $55 million funding for its ADC and IO candidates. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital